Drug Eluting Stents Market is expected to reach USD 10.2 billion by 2031 | Terumo Corp, Stentys S.A, Cook Medical, Boston Scientific Corp., Abbott, Biosensors International

The global drug-eluting stents (DES) market was valued at USD 6.3 billion in 2022 and is anticipated to grow significantly, reaching approximately USD 10.2 billion by 2031. This market is projected to expand at a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2024 to 2031.

The Drug Eluting Stents Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://datamintelligence.com/download-sample/drug-eluting-stents-market?sg

Drug Eluting Stents Market Overview:

The global drug-eluting stents (DES) market has experienced substantial growth in recent years, largely due to the increasing adoption of these stents in interventional cardiology for the treatment of coronary artery disease. Designed to gradually release therapeutic agents, drug-eluting stents help prevent restenosis, thereby improving long-term patient outcomes.

Key trends shaping the market include the growing adoption of biodegradable stents, the development of next-generation DES technologies, expansion into peripheral arterial disease treatments, and the integration of personalized medicine approaches to enhance treatment precision.

Market growth is being propelled by several factors, including technological advancements, a rising global elderly population, the increasing prevalence of cardiovascular diseases, more frequent drug approvals, and a general rise in patient healthcare spending. Together, these dynamics are expected to support the continued expansion of the DES market in the years ahead.

Drug Eluting Stents Market: Shifting Industry Trends

Advancements in Technology to Propel Global Drug-Eluting Stents Market Growth

Ongoing innovations in drug-eluting stent (DES) technology are playing a critical role in driving market expansion. Progress across various aspects of stent development including structural design, drug formulation, and coating techniques-has led to notable improvements in safety, efficacy, and long-term patient outcomes. These technological strides continue to enhance the effectiveness of DES in treating coronary artery disease, fueling global market growth.

According to a 2022 article published in Current Atherosclerosis Reports by the National Library of Medicine, DES design has evolved significantly over time. Initial versions featured thick struts, which were associated with higher risks of inflammation and arterial narrowing. To address these concerns, newer designs have incorporated thinner struts, reducing the likelihood of inflammation and restenosis.

More recently, DES have been engineered with bioresorbable polymers, which gradually dissolve in the body after delivering the therapeutic agent. This advancement may help reduce the risk of late stent thrombosis, a serious complication associated with earlier-generation stents. These innovations not only improve clinical outcomes but also enhance the overall safety profile of DES.

Such continuous technological improvements paired with rising global cardiovascular disease prevalence and a growing emphasis on minimally invasive procedures-are expected to significantly contribute to the expansion of the global drug-eluting stents market in the coming years.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/drug-eluting-stents-market?sg

Strategic Key Players Driving the Drug Eluting Stents Market Forward: Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, and Terumo Corp.

Research Methodology:

The global Drug Eluting Stents Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Drug Eluting Stents Market:

By Coating (Polymer-based coating stents (Non-biodegradable polymer, Biodegradable polymer), Polymer-free coating stents)

By Application (Coronary Artery Diseases, Peripheral Artery Disease)

By End-user (Hospitals, Ambulatory Surgical Centers, Cardiac Centers)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Recent Developments in the Drug-Eluting Stents Market

The drug-eluting stents (DES) market continues to evolve with notable advancements and strategic moves by key players, further enhancing product innovation and expanding market reach. Recent developments include:

✅ May 2023 - CoSo Health Partners with Medinol for EluNIR DES in the U.S.

CoSo Health entered into a distribution agreement with Medinol, a recognized global innovator in implantable medical technologies, to bring the EluNIR thin-strut drug-eluting stent to the U.S. market. This next-generation DES offers improved deliverability and performance, and will be distributed by U.S. Endovascular, which specializes in coronary and peripheral device sales across the United States.

✅ April 2022 - Translumina Launches VIVO ISAR Stent Internationally
Translumina, a global manufacturer of cutting-edge cardiovascular devices, announced the international launch of VIVO ISAR, a next-generation dual-drug, polymer-free coated stent (DDCS). The product was introduced in several international markets, including Europe, and is designed to enhance healing while minimizing long-term complications associated with polymer-based stents.

✅ May 2022 - Medtronic Receives FDA Approval for Onyx Frontier DES
Medtronic plc, a global leader in healthcare innovation, secured FDA approval for its Onyx Frontier drug-eluting stent. This latest-generation DES is engineered for improved deliverability and expanded size matrix, offering enhanced flexibility and precision in complex procedures.

Regional Analysis for Drug Eluting Stents Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Drug Eluting Stents Market Research Industry:

➠ Who leads the Drug Eluting Stents industry and what's their competitive positioning regarding capacity, performance, and profitability?

➠ What growth opportunities and market challenges do Drug Eluting Stents market vendors face?

➠ Which segments show the highest growth potential and market share distribution?

➠ What factors are driving or limiting Drug Eluting Stents market growth?

➠ What are the dominant sales and distribution strategies in the Drug Eluting Stents industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.